Tvardi Therapeutics (TVRD) Free Cash Flow (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Free Cash Flow of -$5.9 million for Q1 2026, down 3.51% sequentially from -$5.7 million in Q4 2025, and up 23.27% YoY from -$4.8 million in Q1 2025.
Tvardi Therapeutics (TVRD) Free Cash Flow (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Free Cash Flow for 14 years, with the latest figure at -$5.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 23.27% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.7 million (down 610.97% YoY) and the FY2025 annual result came in at -$23.5 million, down 21.44% from the prior year.
- Free Cash Flow eased to -$5.9 million in Q1 2026 per TVRD's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $24.5 million in Q2 2024 and troughed at -$34.6 million in Q1 2023.
- A 5-year average of -$13.0 million and a median of -$7.7 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow plunged 1788.35% in 2022, then surged 219.6% in 2024.
- Over 5 years, Free Cash Flow stood at -$23.5 million in 2022, then climbed by 19.45% to -$18.9 million in 2023, then jumped by 74.48% to -$4.8 million in 2024, then slipped by 17.94% to -$5.7 million in 2025, then retreated by 3.51% to -$5.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$5.9 million, -$5.7 million, and -$4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -9.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.90 Mn |
| Mar 31, 2026 | -5.90 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Sep 30, 2024 | -7.68 Mn |
| Sep 30, 2024 | -7.68 Mn |
| Jun 30, 2024 | 24.45 Mn |
| Jun 30, 2024 | 24.45 Mn |
| Mar 31, 2024 | -31.29 Mn |
| Mar 31, 2024 | -31.29 Mn |
| Dec 31, 2023 | -18.94 Mn |
| Dec 31, 2023 | -18.94 Mn |